Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31170532 | 0.92 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1MAPK1LMNASYK | |
| SCHEMBL28956076 | 0.88 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MAPK1LMNASYK | |
| SCHEMBL3737616 | 0.87 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1MAPK1LMNASYK | |
| SCHEMBL20089220 | 0.86 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1MAPK1LMNASYK | |
| SCHEMBL29077734 | 0.86 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1MAPK1SYKSMN1; SMN2 | |
| SCHEMBL3737611 | 0.85 | HDAC3 (0.46) | L3MBTL1ALDH1A1MAPK1LMNASYK | |
| SCHEMBL9787659 | 0.83 | POLB (0.45) | TDP1 | |
| SCHEMBL25211503 | 0.83 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1MAPK1LMNASYK | |
| SCHEMBL10308981 | 0.82 | L3MBTL1 (0.47) | L3MBTL1ALDH1A1MAPK1SYKSMN1; SMN2 | |
| SCHEMBL7332893 | 0.82 | ALDH1A1 (0.56) | L3MBTL1ALDH1A1MAPK1LMNASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414394-B2 | Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-107660202-B | Water-soluble prodrugs | 大日本住友制药肿瘤公司 | 2021-12-24 | — | — | CN | disclosed |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2020-12-17 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | BOSTON BIOMEDICAL, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | BOSTON BIOMEDICAL, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| EP-1420681-A4 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX PHARM INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-7238341-B2 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6991775-B2 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | EPIX MEDICAL, INC. A DELAWARE CORPORATION | 2005-04-07 | — | — | US | disclosed |
| EP-1420681-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | Epix Medical, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | Factor 1A, LLC | 2003-11-20 | — | — | US | disclosed |
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | EPIX PHARMACEUTICALS, INC. | 2003-09-25 | — | — | US | disclosed |
| WO-2003011115-A2 | PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS | EPIX MEDICAL, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180222-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | L3MBTL1 1784/4885ALDH1A1 4848/4885MAPK1 2622/4885 |
| US-20060039861-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | L3MBTL1 1784/4885ALDH1A1 4848/4885MAPK1 2622/4885 |
| US-11414394-B2 | Process for producing a hydrate of a hydrochloride salt of 2,2′-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid | ADH1A, ADH1C, DACH1 | L3MBTL1 4872/4885ALDH1A1 180/4885MAPK1 1581/4885 |
| US-20200392098-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | L3MBTL1 1060/4885ALDH1A1 716/4885MAPK1 3329/4885 |
| US-20190084955-A1 | SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER | NR0B1, NR0B2, NR2C2 | L3MBTL1 1060/4885ALDH1A1 716/4885MAPK1 3329/4885 |
| US-20070185311-A1 | Peptide-Based Multimeric Targeted Contrast Agents | NGLY1, IAPP, NPPA | L3MBTL1 1784/4885ALDH1A1 4848/4885MAPK1 2622/4885 |
| US-20050074411-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | L3MBTL1 1784/4885ALDH1A1 4848/4885MAPK1 2622/4885 |
| US-10800752-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | L3MBTL1 1060/4885ALDH1A1 716/4885MAPK1 3329/4885 |
| US-20030216320-A1 | Peptide-based multimeric targeted contrast agents | NGLY1, IAPP, NPPA | L3MBTL1 1784/4885ALDH1A1 4848/4885MAPK1 2622/4885 |
| US-10183925-B2 | Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer | NR0B1, NR0B2, NR2C2 | L3MBTL1 1060/4885ALDH1A1 716/4885MAPK1 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.